Ultime notizie per Alpha Tau Medical (NASDAQ:DRTS) Azioni

Alpha Tau Medical

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.

Alpha Tau Medical Ltd

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) with a Buy and lowers the price target from $45 to $41.

News

Price Target

Analyst Ratings

RNAC

HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $41

Ciena's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) short percent of float has risen 3.56% since its last report. The company recently reported that it has 6.11 million shares sold short, which is 5.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.38 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ciena Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731093400_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ciena has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ciena's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ciena's peer group average for short interest as a percentage of float is 7.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

CIEN

Peering Into Ciena's Recent Short Interest

Kraft Heinz's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NYSE">KHC</a>) short percent of float has fallen 3.77% since its last report. The company recently reported that it has 33.76 million shares sold short, which is 3.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kraft Heinz Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731093395_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kraft Heinz has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Kraft Heinz's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kraft Heinz's peer group average for short interest as a percentage of float is 4.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Kraft Heinz's Recent Short Interest

Cheniere Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) short percent of float has risen 7.09% since its last report. The company recently reported that it has 3.39 million shares sold short, which is 1.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cheniere Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731093389_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cheniere Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cheniere Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cheniere Energy's peer group average for short interest as a percentage of float is 3.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Cheniere Energy's Recent Short Interest

Barclays analyst Saket Kalia maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $240 to $260.

VEEV

Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $260

HC Wainwright &amp; Co. analyst Robert Burns reiterates OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) with a Buy and maintains $40 price target.

Reiteration

OKUR

HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $40 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) with a Buy and lowers the price target from $6 to $5.

RLYB

HC Wainwright & Co. Maintains Buy on Rallybio, Lowers Price Target to $5

<a href="https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales">https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales</a>
&nbsp;
Toyota Motor Corp.'s North American chief operating officer criticized the US's policies promoting speedy adoption of electric vehicles, calling them "de facto mandates" out of sync with consumer demand.

Management

Global

'Toyota Executive Lashes Out At U.S. Regulations Promoting EV Sales' - Bloomberg News

Needham analyst Chris Pierce maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Buy and raises the price target from $27 to $39.

CARG

Needham Maintains Buy on CarGurus, Raises Price Target to $39

Barclays analyst Benjamin Budish maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Overweight and raises the price target from $50 to $57.

Barclays Maintains Overweight on Carlyle Group, Raises Price Target to $57

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Barclays analyst Jared Shaw maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Overweight and raises the price target from $56 to $64.

Barclays Maintains Overweight on Synovus Finl, Raises Price Target to $64

Motorola Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com/quote/MSI/earnings">FY24 adjusted EPS guidance above estimates on Thursday.</a>
Motorola Solutions reported quarterly earnings of $3.74 per share which beat the analyst consensus estimate of $3.38 per share. The company reported quarterly sales of $2.79 billion which beat the analyst consensus estimate of $2.76 billion.
&#8220;Our third-quarter results were exceptional, with record Q3 revenue, earnings and cash flow,&#8221; said Greg Brown, chairman and CEO, Motorola Solutions. &#8220;We achieved strong growth across the board, and I&#8217;m pleased with the momentum of our business. As a result, we&#8217;re again raising our revenue and earnings expectations for the full year.&#8221;
Motorola Solutions shares gained 6.8% to trade at $501.80 on Friday.
These analysts made changes to their price targets on Motorola Solutions following earnings announcement.
<ul>
<li>Raymond James analyst Adam Tindle maintained Motorola with an Outperform and raised the price target from $425 to $515.</li>
<li>Barclays analyst Tim Long maintained the stock with an Overweight and raised the price target from $467 to $529.</li>
</ul>
Considering buying MSI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png" alt="" class="wp-image-638367" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Earnings

Markets

These Analysts Raise Their Forecasts On Motorola Solutions Following Q3 Earnings

HC Wainwright &amp; Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) with a Buy and maintains $13 price target.

TNGX

HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target

Barclays analyst Julian Mitchell maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Underweight and raises the price target from $245 to $255.

Barclays Maintains Underweight on Rockwell Automation, Raises Price Target to $255

WIIM

Canopy Growth shares are trading lower. The company reported Q2 financial results.

<a href="https://www.devdiscourse.com/article/technology/3150879-nhtsa-raises-concerns-over-teslas-fsd-promotion">https://www.devdiscourse.com/article/technology/3150879-nhtsa-raises-concerns-over-teslas-fsd-promotion</a>
The National Highway Traffic Safety Administration (NHTSA) voiced concerns about Tesla's social media messaging concerning its Full Self-Driving (FSD) software.
NHTSA's worry stems from Tesla's implications that their FSD can be used as a robotaxi, negating the need for constant driver attention. This issue has elevated in importance following an investigation the agency initiated in October into 2.4 million Tesla vehicles equiped with FSD software.
The inquiry came after four reported accidents, including a fatal crash this year. In an email from May 14 released publicly, the NHTSA criticized Tesla's social media announcements for potentially misleading the public into viewing the FSD as anything other than a driver assist system demanding vigilant supervision and occasional driver intervention.

Legal

TSLA

"The National Highway Traffic Safety Administration Expressed Concerns Regarding Tesla's Social Media Posts That Imply Its Full Self-Driving Software Can Function As A Robotaxi Without Driver Supervision. This Comes After The NHTSA Opened An Investigation Into Tesla's FSD Software Following Four Collisions, Including A Fatal Crash In 2023." - Dev Discourse

HC Wainwright &amp; Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Buy and raises the price target from $19 to $20.

RLAY

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $20

MNMD

Mind Medicine shares are trading higher after the company reported better-than-expected Q3 EPS results.

PRQR

ProQR Therapeutics shares are trading higher afer HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $5 to $10.

Piper Sandler analyst Jason Bednar maintained a Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report) today and set a price target of $7.00....

Piper Sandler Reaffirms Their Buy Rating on Alpha Tau Medical Ltd (DRTS)

Ashiq Mubarack, an analyst from Citi, has initiated a new Buy rating on Alpha Tau Medical Ltd (DRTS). Ashiq Mubarack has given his Buy rating due t...

Buy Rating on Alpha Tau Medical Ltd. Amidst Promising Alpha DaRT Cancer Treatment Trials and Solid Financials

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report). The associated price target ...

Buy Rating Reaffirmed for Alpha Tau Medical Ltd Amid Strong Clinical Results and Solid Financial Management

Alpha Tau Medical Ltd (DRTS) has released an update. Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, will be showcasing its innov...

Alpha Tau Medical to Showcase Cancer Therapy at Global Conferences

Alpha Tau Medical Ltd (DRTS) has released an update. Alpha Tau Medical Ltd. has announced FDA approval for an Investigational Device Exemption to s...

Alpha Tau's Alpha DaRT Gains FDA Study Approval

Alpha Tau Medical Ltd (DRTS) has released an update. Alpha Tau Medical Ltd., a pioneer in alpha-radiation cancer therapy, has successfully treated ...

Alpha Tau's Alpha DaRT Advances Lung Cancer Treatment

Buy Rating Justified for Alpha Tau Medical Ltd. on Back of Promising Alpha DaRT Clinical Developments and Market Potential

Alpha Tau (DRTS) Medical announced that it has been accepted into the prestigious Total Product Life Cycle, TPLC, Advisory Program, TAP, Pilot of t...

Alpha Tau announces acceptance into FDA's TPLC TAP Pilot

Alpha Tau Medical Ltd (DRTS) has released an update. Alpha Tau Medical Ltd. has been accepted into the FDA's Total Product Life Cycle Advisory Prog...

Alpha Tau Joins FDA Program to Advance Cancer Therapy

Alpha Tau Medical Ltd's Strategic Advancements and Clinical Trials Drive Buy Rating

DRTS

Press Releases

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Health Care

Alpha Tau to Present at the Jefferies Global Healthcare Conference

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Events

Sidoti Events, LLC's Virtual September Small-Cap Conference

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

General

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

CNXN

DRTSW

GOEV

INBS

ROCK

SKYH

SOWG

TSX:ISV

TSX:TPZ

Accuray

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

BrainsWay Ltd. - American Depositary Shares

BrainsWay

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Alpha Tau Medical

Notizie

Ultime notizie per Alpha Tau Medical (NASDAQ:DRTS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO